Anika Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Anika Therapeutics, Inc. (ANIK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $12.71 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-03
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $27.93, a 5.90% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $29.68, a 4.62% increase year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $28.37, a 16.73% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $12.71, a 54.74% decline from fiscal 2024.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $28.08, a 1.75% decline from fiscal 2023.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $28.58, a 1.82% increase from fiscal 2022.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $28.07, a 26.29% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $12.71 10-K · filed 2026-03-03 | |||||
| 2025-06-30 | $12.71 10-Q · filed 2025-11-05 | $13.99 10-Q · filed 2025-07-30 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-09 | |||||
| 2024-12-31 | $28.08 10-K · filed 2025-03-17 | |||||
| 2024-09-30 | $28.13 10-Q · filed 2024-11-04 | |||||
| 2024-06-30 | $28.18 10-Q · filed 2024-08-08 | |||||
| 2024-03-31 | $27.93 10-Q · filed 2024-05-08 | |||||
| 2023-12-31 | $28.58 10-K · filed 2024-03-15 | |||||
| 2023-09-30 | $28.63 10-Q · filed 2023-11-03 | |||||
| 2023-06-30 | $29.51 10-Q · filed 2023-08-08 | |||||
| 2023-03-31 | $29.68 10-Q · filed 2023-05-09 | |||||
| 2022-12-31 | $28.07 10-K · filed 2023-03-16 | |||||
| 2022-09-30 | $27.60 10-Q · filed 2022-11-09 | |||||
| 2022-06-30 | $23.21 10-Q · filed 2022-08-04 | |||||
| 2022-03-31 | $28.37 10-Q · filed 2022-05-06 | |||||
| 2021-12-31 | $38.08 10-K · filed 2022-03-11 | |||||
| 2021-09-30 | $37.67 10-Q · filed 2021-11-05 | |||||
| 2021-03-31 | $34.07 10-Q · filed 2022-05-06 | |||||
| 2020-12-31 | $38.20 10-K · filed 2022-03-11 | $16.31 10-K · filed 2021-03-05 | ||||
| 2019-12-31 | $34.02 10-K · filed 2022-03-11 | $14.73 10-K · filed 2021-03-05 | ||||
| 2018-12-31 | $20.01 10-K/A · filed 2021-04-26 | |||||
| 2017-12-31 | $16.87 10-K · filed 2019-02-27 | |||||
| 2016-12-31 | $16.65 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |